Towa Pharmaceutical Co(JP:4553)
¥3,345.00-35.00 (-1.04%)
JP:4553
Towa Pharmaceutical Co earnings date
¥3,345.00
At close:-35.00 (-1.04%)
Want to see JP:4553 full AI Analyst Report?
Towa Pharmaceutical Co (4553) Q2 2026 Earnings Report
0 Followers
JP:4553 Q2 2026 EPS Results
- Actual EPS
- JPY 25.60
- Consensus EPS
- JPY 101.18
- Beat/Miss
- Missed by -JPY 75.58
- One Year Ago EPS
- JPY 115.80
JP:4553 Q2 2026 Revenue Results
- Actual Revenue
- JPY 70.87B
- Expected Revenue
- JPY 70.90B
- Beat/Miss
- Missed by -JPY 28.33M
- YoY Revenue Growth
- +8.49%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 11/11/2026
- Time
- TBA
- Conference Call
- Wednesday, November 11, 2026
JP:4553 Upcoming Earnings
Towa Pharmaceutical Co's next earnings date is estimated for February 15, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4553 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 15, 2027 | 2026 (Q3) | 156.86- | 180.15 | ― | ― |
| Nov 11, 2026 | 2026 (Q2) | 101.1825.60 | 115.8 | -77.89% (-90.20) | |
| Aug 06, 2026 | 2026 (Q1) | ―112.36 | 51.06 | 120.05% (+61.30) | |
| May 14, 2026 | 2025 (Q4) | 107.89-240.35 | 88.61 | -371.24% (-328.96) | |
| Feb 13, 2026 | 2025 (Q3) | ―180.15 | 163.93 | 9.89% (+16.22) | |
| Nov 10, 2025 | 2025 (Q2) | 62.02115.80 | 21.53 | 437.85% (+94.27) | |
| Aug 07, 2025 | 2025 (Q1) | 63.4651.06 | 111.64 | -54.26% (-60.58) | |
| May 15, 2025 | 2024 (Q4) | 113.8988.61 | -14.71 | 702.22% (+103.32) | |
| Feb 13, 2025 | 2024 (Q3) | 57.66163.93 | 92.77 | 76.71% (+71.16) | |
| Nov 12, 2024 | 2024 (Q2) | 49.6221.53 | 44.75 | -51.89% (-23.22) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
